Cancer Drug Price Cuts Reveal Excessive Pharmaceutical Markups in India

The National Pharmaceutical Pricing Authority has published a revised Maximum Retail Price schedule for 543 brands of oncology medicines across 137 non-scheduled formulations, triggering debate among healthcare advocacy groups regarding historical retail markups. Issued by the pricing regulator under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the updated rates take effect on November 9, 2026, enforcing an administrative ceiling that limits trade margins to 30% of the maximum retail price, excluding GST. The central government projects that the regulatory intervention will reduce retail prices by up to 70% for selected therapies.

Official price comparisons demonstrate sharp reductions across key oncology treatments administered in clinical settings. The reported price of Thiotepa, a therapeutic compound utilized in chemotherapy and conditioning procedures, fell from ₹80,072 to ₹7,150 for a 100 mg vial, marking a price reduction of nearly 91%. That adjustment lowered the expense of a 100 mg vial by around ₹72,900, significantly easing financial burdens for patients requiring hospital-administered treatment. Similarly, retail prices for palbociclib, prescribed for advanced breast cancer, declined from approximately ₹40,421 to ₹2,720 per commercial pack. The 137 non-scheduled medicines covered under the price ceiling include immunotherapy drugs deployed in the treatment of over 20 types of cancer.

Under the updated pricing schedule, the maximum retail price for RPG Life Sciences Ltd's Anastrozole 1 mg tablets dropped from 695.76 to 73.00, according to Press Information Bureau.

During a 2019 pilot rationalisation exercise capping trade margins on 42 anti-cancer drugs at 30%, the prices of 526 non-scheduled brands were reduced by up to 90%, according to Press Information Bureau.

Healthcare Advocates Critique Margin Methodology

Public health organizations, including Jan Swasthya Abhiyan India, stated that while immediate price reductions deliver relief to patients, relying exclusively on trade margin caps fails to address underlying manufacturing costs. The advocacy group pointed out that allowing a 42.8% markup over the Price to Stockist legitimizes excessive margins across hospital distribution chains that often involve direct vendor relationships.

Advocates emphasized that a one-time retail reduction is insufficient without permanent statutory margin ceilings and independent cost audits, arguing that a markup comparable to the 16% margin applied to scheduled formulations under the Drug Price Control Order framework would produce greater affordability. Furthermore, health groups noted that patented cancer therapies remain priced beyond the reach of average households.

Clinical Perspectives on Treatment Adherence

Medical oncologists noted that elevated medication costs directly contribute to financial toxicity, compelling patients to skip prescribed doses, delay therapy initiation, or discontinue clinical care prematurely. Clinical specialists observed that lower drug costs support completed therapeutic regimens, but urged policymakers to complement retail price ceilings with broader insurance coverage and expanded public reimbursement mechanisms.

Healthcare institutions and retail pharmacies will be required to display the revised prices once the regulatory mandates become enforceable on November 9, with consumers able to monitor compliance via official digital verification platforms.

Manufacturers must inform the pricing authority of their revised prices within 7 days of publication, according to Press Information Bureau.